Last reviewed · How we verify
Epcoritamab, tafasitamab and lenalidomide
Epcoritamab, tafasitamab and lenalidomide is a Small molecule drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. It is currently in Phase 2 development.
At a glance
| Generic name | Epcoritamab, tafasitamab and lenalidomide |
|---|---|
| Sponsor | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (PHASE2)
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epcoritamab, tafasitamab and lenalidomide CI brief — competitive landscape report
- Epcoritamab, tafasitamab and lenalidomide updates RSS · CI watch RSS
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI
Frequently asked questions about Epcoritamab, tafasitamab and lenalidomide
What is Epcoritamab, tafasitamab and lenalidomide?
Epcoritamab, tafasitamab and lenalidomide is a Small molecule drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea.
Who makes Epcoritamab, tafasitamab and lenalidomide?
Epcoritamab, tafasitamab and lenalidomide is developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (see full Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea pipeline at /company/grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea).
What development phase is Epcoritamab, tafasitamab and lenalidomide in?
Epcoritamab, tafasitamab and lenalidomide is in Phase 2.